Evidence map›Paper›PMID 33442514›Full record

Article3 Biotech2021

Adriamycin inhibits glycolysis through downregulation of key enzymes in

Uma Priya Mohan, Selvaraj Kunjiappan, P B Tirupathi Pichiah, Sankarganesh Arunachalam

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in 3 Biotech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Uma Priya MohanCenter for Cardiovascular and Adverse Drug Reactions, Department of Biotechnology, School of Bio and Chemical Engineering, Kalasalingam Academy of Research and Education, Krishnankoil, Virudhunagar Dt., Tamil Nadu 626126 India.
Selvaraj KunjiappanDepartment of Biotechnology, Kalasalingam Academy of Research and Education, Krishnankoil, Virudhunagar, Tamil Nadu 626126 India.
P B Tirupathi PichiahDepartment of Animal Science, School of Life Sciences, Bharathidasan University, Tiruchirappalli, Tamil Nadu 620024 India.
Sankarganesh ArunachalamCenter for Cardiovascular and Adverse Drug Reactions, Department of Biotechnology, School of Bio and Chemical Engineering, Kalasalingam Academy of Research and Education, Krishnankoil, Virudhunagar Dt., Tamil Nadu 626126 India.ORCID 0000-0003-2857-4877
Kalasalingam Academy of Research and Education · INBharathidasan University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adriamycin is a widely used drug for the treatment of various types of cancers, but its clinical application is limited because of irreversible dilated cardiomyopathy. The incidence of cardiomyopathy is a consequence of disrupted energy production, which could be related to the defects in glycogen, lipid and mucopolysaccharide metabolism. We explored the effect of Adriamycin on enzymes involved in glycolysis and apoptotic genes through molecular docking. We used

Indexed as

AdriamycinATPCardiomyopathyEnolase and Mg2+GlycolysisMolecular dockingPhosphofructokinase

Identifiers

PMID33442514
PMCPMC7778664
OpenAlexW3118667276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.